MSC303 Subcutaneous Injection for the Treatment of Immunologic Glomerular Disease.
Trial statusNot yet recruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-65
SponsorShanghai Changzheng Hospital
About this trial
This study will evaluate the safety and efficacy of MSC303 in patients with Immune glomerular diseases.
Eligibility criteria
Qualifiers
Aged 18 to 65 years (including boundary values), gender unspecified；
Willing to participate voluntarily in this clinical study and with good compliance；
Diagnosed with lupus nephritis(LN);
diagnosed with ANCA-associated glomerulonephritis (ANCA-GN);
Disqualifiers
History of severe allergic reaction to humanized monoclonal antibodies, or known allergy to any component of MSC303；
Active infection requiring antibiotic treatment；
Concomitant with other serious diseases；
Patients with congenital immunoglobulin deficiency；
Trial design
Treatments tested in this trial
- Injection of MSC303
Treatment groups
12 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov